Two phase 3 trials reported a prolonged survival in the third‐line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.
Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
Brunetti, Oronzo;Solimando, Antonio Giovanni;Argentiero, Antonella
2019
Abstract
Two phase 3 trials reported a prolonged survival in the third‐line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
CCR3-7-2379.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
323.1 kB
Formato
Adobe PDF
|
323.1 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
